The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng ® (satralizumab-mwge) for the treatment of ...
Zacks Investment Research on MSN
Roche gets FDA approval for Enspryng in thyroid eye disease
Roche RHHBY announced that the FDA has approved Enspryng (satralizumab) for the treatment of thyroid eye disease (TED). The ...
The supplemental indication for satralizumab, already sold for a rare neuroinflammatory disease, is another example of the recent marked growth in approved treatments for thyroid eye disease.
Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.
Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, ...
Scientists have discovered a hidden cleanup system at the back of the eye that drains fluid and waste through a previously ...
Oku Digital Health, which was recently launched from Topcon Healthcare, will use a network of more than 10,000 healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results